HTH director Stefan Krauss receives funding from the The Norwegian Cancer Society

Project summary
There are 1500 melanoma patients annually in Norway (87000 cases in the US estimated for 2017). Checkpoint inhibitor based immune therapy comprises a major breakthrough in cancer therapy of melanoma. However, checkpoint inhibition does not work in all cancer patients, and identifying resistance factors has become a major research branch in the field. WNT/b-catenin signaling has been identified as the most significant resistance factor in melanoma. We have developed an international leading WNT inhibitor. We will now develop a Tumor-on-a-Chip platform that should reliably copy the cancer/immune interplay and hence give us answers how the WNT inhibitor and other therapeutic reagents best works on melanoma and other cancers.